Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab + pertuzumab + docetaxel vs standard regimen in early HER2-positive breast cancer
2015-002323-25Phase 3Active
- Sponsor
- Finnish Breast Cancer Group
- Start
- Jun 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of trastuzumab, pertuzumab and docetaxel in breast cancer (2 arms), sponsored by Finnish Breast Cancer Group. Primary endpoint: Invasive disease-free survival. Started Jun 2015; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-002323-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002323-25.